abstract BACKGROUND AND OBJECTIVE: The efficacy of Saccharomyces boulardii for treatment of childhood diarrhea remains unclear. Our objective was to systematically review data on the effect of S. boulardii on acute childhood diarrhea.
Diarrhea is defined by the World Health Organization (WHO) as 3 or more passages of loose or watery stool and increments in stool frequency in a 24-hour period. The most common cause of diarrhea is a gut infection (viral, bacterial, and parasitic). Other causes include side effects of medicine (especially antibiotics), infections not associated with the gastrointestinal tract, food poisoning, and allergy. 1 Diarrhea is also categorized into acute (lasts several hours or days) and persistent (continues for 14 days or longer). Diarrhea with any cause and any period of time may lead to dehydration and even may be lethal in infants, children, and the elderly if not corrected immediately. 2 Globally, ∼1.7 billion cases of diarrheal disease occur every year, resulting in nearly 760 000 deaths in children younger than age 5 years, especially in developing countries. 3 The treatment of choice for dehydration caused by diarrhea is the replacement of the lost fluids and electrolytes by oral rehydration solution (ORS). As rehydration therapy does not significantly decrease the frequency/length of diarrhea, scientists are interested in adjunctive treatments. 4 Probiotics as one of the alternative approaches for prevention and treatment of diarrhea are living microorganisms that provide various beneficial health effects in humans. It is proposed that probiotics can modulate the immune response, 5 produce antimicrobial agents, 6 and compete in nutrient uptake and adhesion sites with pathogens. 7 Well-known probiotics with claimed health-improving properties are intestinal lactic acid bacteria like Lactobacillus rhamnosus, Lactobacillus casei, and Lactobacillus johnsonii, and the yeast Saccharomyces. 8 Saccharomyces boulardii is a beneficial yeast that was first isolated from lychee and mangosteen fruit. In many clinical trials, S. boulardii has been shown to be effective in prevention and management of diarrhea, especially antibiotic-associated diarrhea. S. boulardii can be administered simultaneously to prevent antibiotic-associated diarrhea owing to its resistance to most antibiotics. However, a recent randomized controlled trial reported S. boulardii was not effective in preventing the development of antibiotic-associated diarrhea in elderly hospitalized patients. 9 According to our knowledge, there is 1 systematic review about the effectiveness of S. boulardii in childhood acute diarrhea. 10 To provide an update, Szajewska et al added data from 3 studies to their previous review. They reported a reduction in the duration of the diarrhea (1.08 days) in those treated with S. boulardii compared with controls, although there was significant heterogeneity (I 2 = 89%) in results among the studies. 11 However, they proposed to conduct more clinical trials to further specify groups (by etiology of diarrhea or hospitalization) driving better clinical response to S. boulardii treatment and to define the most effective dosage. 10 The aim of the current study was to systematically review published studies that assessed the efficacy and safety of S. boulardii on the treatment of childhood diarrhea, taking new publications into account. To maximize use of available data, we also included open labeled studies in our review. We further tried to evaluate whether cause, severity of diarrhea, and treatment dose can explain the difference between study results.
METHODS

Protocol and Registration
PRISMA statement was followed for reporting this systematic review and meta-analysis. 12 Search strategy and inclusion criteria were defined and documented in a protocol. The review protocol has been registered in the International Prospective Register of Systematic Reviews (PROSPERO) under registration number CRD42013005869. 
Eligibility Criteria
All randomized controlled trials regardless of language or publication date or state (published, unpublished, in press, and in progress) were included. Participants had to be children (0 to 18 years of age), male or female of any ethnic group with acute diarrhea (#14 days). We were flexible about definition of diarrhea. Patients in the experimental groups had to receive S. boulardii at any dose and in any form (eg, capsule, sachet, yogurt). Trials investigating products that do not label S. boulardii dose were not considered. Patients in the control groups had to receive placebo or no treatment control. Primary outcomes were duration of diarrhea, diarrhea lasting $4 days, and stool frequency on day 2 after intervention. Secondary outcomes were diarrhea lasting $3 days, stool frequency on day 3 after intervention, and harms.
Study Selection
Title, keywords, and abstract of publications identified according to the above described search strategy were independently screened by 2 reviewers (Dr Akbari and Dr Feizizadeh). Inclusion criteria for title and abstract screening were randomized controlled trials, children who had diarrhea, and studies that compare S. boulardii with placebo or no therapy. The same reviewers independently assessed full-texts of relevant studies for final inclusion. Excluded publications and the reasons for their exclusion were presented (Supplemental Table 2 ). Discrepancies between the reviewers were resolved through discussion by the entire review team (Dr Feizizadeh, Dr Salehi-Abargouei, and Dr Akbari).
Data Collection Process and Data Items
Tworeviewers(DrAkbariandDrFeizizadeh) independently extracted details of included studies. Information on authors, publication year, study design, study location, source of funding, duration of study, inclusion criteria, exclusion criteria, causes of diarrhea, nutritional status, hydration status, the number of patients who completed the study, interventions, outcomes, adverse effects, and results was extracted from each study. We tried to contact the authors of included studies for missing variable and relevant information. [13] [14] [15] [16] [17] [18] [19] [20] Disagreements were resolved by discussion.
Risk for Bias in Individual Studies
Risk for bias of each study was assessed by 2 reviewers (Dr Akbari and Dr Feizizadeh) based on the Cochrane Collaboration' s risk for bias tool 21 using generation of allocation sequence, allocation concealment, blinding, and loss to follow-up. We classified these elements as Yes (low risk for bias), No (high risk for bias), or Unclear.
Statistical Analysis
Mean 6 SD of diarrhea duration and number of stools on 2 and 3 days after intervention was used to calculate the mean difference (MD) and its SE as effect size to be used in meta-analysis. We also used relative risk (RR) of treatment on days 3 and 4 after the start of probiotic use to calculate log RR and its corresponding SE for meta-analysis. 22 Overall effect for each meta-analysis was derived by using a random effects model, which takes between-study variation into account. 22 Statistical heterogeneity between studies was evaluated by using Cochran' s Q test and I-squared. 23 Sensitivity analysis was used to explore the extent to which inferences might depend on a particular study or a number of publications. Subgroup analysis based on cause of diarrhea, severity of diarrhea, and dosage of probiotic was also performed to find possible sources of heterogeneity. Publication bias was evaluated by looking over Begg' s funnel plots. 24 Formal statistical assessment of funnel plot asymmetry was also done using Egger' s regression asymmetry test and Begg' s adjusted rank correlation test. 24 All statistical analyses were conducted by using Stata version 11.2 (Stata Corp, College Station, TX). P values , .05 were considered statistically significant.
RESULTS
Study Characteristics
The study selection process is depicted in Fig 1. Our search strategy resulted in 1248 studies; of them 304 were duplicates. After reading titles/abstracts, 36 potentially relevant studies were identified. Fourteen studies were excluded after full-text assessment for the following reasons: 3 studies evaluated the preventive effect of probiotic on diarrhea, [25] [26] [27] 3 studies had no control group, 28-30 2 were evaluated in patients who had persistent diarrhea, 31,32 2 were secondary publication of a study done by Cetina-Sauri et al, 33 ,34 1 included patients who had Blastocystis hominis infection without diarrhea, 35 1 used a mixed probiotic preparation for intervention, 36 data from 1 study were not reported, 15 and full-text of 1 study was not available. 20 Characteristics of excluded studies are presented in Supplemental Table 2 .
In total, 22 studies were included in our systematic review. Characteristics of included studies are summarized in Table 1. Trials were performed in France, Mexico, Turkey, Pakistan, Italy, Argentina, Myanmar, Bolivia, Brazil, Azerbaijan, Indonesia, and India, and published between 1985 and 2013. All studies were published in English except 1 study that was written in Azarbayejani. 18 Twenty of the included studies were published as an original article, 1 as a letter, 37 and 1 as a meeting abstract. 38 Twenty-two included studies had a total of 2440 patients in their intervention or control groups (1225 interventions, 1215 controls). Patients were aged from 1 month to 15 years. Twelve studies enrolled inpatients, 13, [16] [17] [18] [19] [39] [40] [41] [42] [43] [44] [45] 5 enrolled outpatients, 14,37,46-48 and 2 enrolled both inpatients and outpatients. 49, 50 There was no information about the hospitalization state of participants in 3 studies. 38, 51, 52 For most of the studies the daily dosage of S. boulardii was 250 to 750 mg (10 9 to 10 10 colony-forming units). One study used 4 3 10 10 lyophilized cells of S. boulardii 44 and 1 used 5 3 10 6 living microorganisms per day. 52 Duration of intervention was 5 to 10 days. In 2 studies duration of treatment was not stated. 42, 51 
Risk of Bias Within Included Studies
The methodological quality of included studies is shown in Supplemental Table 3. Briefly, only 1 study was adequate for all of the 4 methodological quality assessment parameters 43 and 1 was inadequate for all 4 parameters. 46 Eight studies were rated as adequate 14, 16, 19, 37, 43, 45, 48, 51 and 4 were inadequate for generation of the allocation sequence, 17, 39, 46, 47 and the method used for allocation sequence was unclear in 10 studies. 13, 18, 38, [40] [41] [42] 44, 49, 50, 52 Four studies were adequate, 14, 43, 45, 48 14 studies were unclear, 13, 16, 18, 19, 37, 38, [40] [41] [42] 44, [49] [50] [51] [52] and 4 studies were inadequate (as they used a method such as alternation. 17, 39, 46, 47 ) for allocation concealment. Six studies were adequate, 41, [43] [44] [45] 48, 50 12 studies were inadequate, 13, 14, [16] [17] [18] [19] 37, 39, 46, 47, 49, 52 and 4 studies were unclear for blinding. 38, 40, 42, 51 Loss to follow-up was adequate (#10%) in 12 studies 13, 16, 17, 19, [37] [38] [39] [40] 43, 47, 49, 50 ; 7 studies were considered inadequate 14, 41, [44] [45] [46] 48, 52 and 3 studies unclear for loss to followup. 18, 47, 51 The overall quality was assessed and 4 studies were rated as "good" (low risk for bias), 43, 45, 48, 50 13 studies rated as "fair," which were susceptible to some bias, 13, 14, 16, 18, 19, 37, 38, [40] [41] [42] 44, 49, 51 and 5 studies rated as "poor" (high risk for bias). 17, 39, 46, 47, 52 Findings From Meta-analysis Seventeen studies (2102 participants) reported duration of diarrhea. 13, 14, 16, 17, 19, 37, 38, 41, 42, [44] [45] [46] [47] [48] [49] 51, 52 The reduction in diarrhea duration ranged from 250.4 to 6.0 hours among included studies. Our analysis shows a reduction in duration of diarrhea in the treatment group compared with the control group (MD = 219.7; 95% CI, 226.05 to 213.34; P , .001) (Fig 2) . The heterogeneity test for diarrhea duration showed a significant heterogeneity between 17 studies (Cochrane Q test, P , .001, I 2 = 64.5%). To explore the possible sources of heterogeneity we examined subgroup analysis based on cause of diarrhea, hospitalization status, probiotic dose used for intervention, and blinding. In brief, subgroup
FIGURE 1
Flow diagram of the study selection process. Table 2 .
REVIEW ARTICLE
Five studies (846 participants) evaluated stool frequency in day 2 after intervention (Fig 3) and 9 studies (1227 participants) reported the risk for diarrhea lasting $4 days (Fig 4) . Pooling the results of the trials showed that S. boulardii reduces the stool frequency on day 2 (MD = 20.74; 95% CI, 21.38 to 20.10; P = .023) and the risk ratio (RR) of diarrhea on day 4 after intervention in the S. boulardii group compared with the control group was 0.38 (95% CI, 0.24 to 0.59; P , .001). The heterogeneity test for the stool frequency on day 2 revealed a significant heterogeneity between 5 studies (Cochrane Q test, P , .001, I 2 = 91.6%). The heterogeneity test for RR of diarrhea on day 4 showed a significant heterogeneity between 9 studies (Cochrane Q test, P = .001, I 2 = 71.1%). The RR of diarrhea lasting $4 days after removing the Khan et al study from meta-analysis was 0.42 (95% CI, 0.28 to 0.63) and heterogeneity decreased (Cochrane Q test, P = .003, I 2 = 67.3%).
Six studies (947 participants) reported stool frequency on day 3 (Fig 5) and 8 studies (1227 participants) evaluated diarrhea lasting $3 days (Fig 6) . Metaanalysis showed that using S. boulardii reduced stool frequency on day 3 (MD = 21.24; 95% CI, 22.13 to 20.35; P = .006). The heterogeneity test for the stool frequency on day 3 showed a significant heterogeneity between 6 studies (Cochrane Q test, P , .001, I 2 = 93.9%). The mean difference of stool frequency on day 3 after removing a study done by Canani et al was 21.62 (95% CI, 21.85 to 21.40); after removing this study, there was no evidence of heterogeneity anymore (Cochrane Q test, P = .657, I 2 = 0.0%). In contrast to other studies, Canani et al performed their trial in a developed country, which may explain the difference in results. The overall RR of diarrhea lasting $3 days was 0.41 (95% CI, 0.27 to 0.60; P , .001). The heterogeneity test for RR of diarrhea on day 3 showed a significant heterogeneity between 8 studies (Cochrane Q test, P , .001, I 2 = 84.7%). The RR of diarrhea lasting $3 days after removing the Khan et al study from meta-analysis was 0.51 (95% CI, 0.40 to 0.64) and heterogeneity decreased (Cochrane Q test, P = .050, I 2 = 52.4%).
Other Outcomes
The effect of using S. boulardii for reduction of vomiting duration was evaluated by 6 trials. Five studies reported vomiting was similar in the S. boulardii group and the control group. 16, 38, 41, 49, 52 Burande et al observed average time of vomiting was shorter in the S. boulardii group compared with the control group. 37 Fever duration was evaluated by 3 studies that showed there was no significant difference between the 2 groups. 16, 41 Two studies reported duration of hospitalization. Kurugöl et al reported a decrease in the duration of hospitalization in the S. boulardii group compared with the placebo group. 41 In another study no statistically significant difference was observed in the hospitalization time between the S. boulardii group and the control group. 16 Two studies evaluated weight gain and both of them reported no significant difference of gain between S. boulardii and control groups. 13, 45 The studies did not report any serious adverse effects related to using S. boulardii.
Kurugöl et al reported that 1 child had a complaint meteorism but that does not provide any information of the group allocation. 41 
Sensitivity Analysis and Publication Bias
Findings from sensitivity analysis showed that no particular study significantly affected the mean duration of diarrhea, RR of diarrhea lasting $3 days, and diarrhea lasting $4 days and mean stool frequency on day 3. Sensitivity analysis revealed that excluding trials done by Khan 
FIGURE 3
Forest plot showing the effect of S. boulardii on mean stool frequency on day 2.
stool frequency on day 2 to nonsignificant results.
The publication bias was assessed by using a funnel plot depicting the MD in duration of diarrhea against their SE as a measure of precision (Fig 7) . Although a slight asymmetry was seen in Begg' s funnel plot, there was no evidence of publication bias using asymmetry tests (Egger' s test, P = .146; Begg' s test, P = .458).
DISCUSSION
In this systematic review and metaanalysis we found that supplementing S. boulardii in children who have diarrhea has a beneficial effect on different diarrhea outcomes. Meta-analysis of the included studies showed the duration of acute childhood diarrhea (children aged 1 month to 15 years) reduced, with an MD of 19.7 hours, by using S. boulardii as adjunct therapy. Our findings also indicate that S. boulardii may be effective in treating acute childhood diarrhea regardless of its causes (bacteria, virus, or protozoa) and can significantly decrease RR of diarrhea on days 3 and 4 after intervention and stool frequency on days 2 and 3 compared with controls. We could include 22 trials in the present review, whereas previously published reviews trying to assess the effectiveness of S. boulardii for acute childhood diarrhea could include a limited number of studies. For example, a meta-analysis done by Szajewska et al could include only 7 studies and reported that duration of diarrhea reduced by 1.08 days (25.92 hours) in children who received S. boulardii compared with controls. They only included randomized controlled trials and did not report MD of frequency of diarrhea on days 2 and 3 and the RR of diarrhea on days 3 and 4. There have been some systematic reviews on the effect of probiotics on acute diarrhea; however, they did not specifically focus on S. boulardii alone. A systematic review was performed on the effectiveness of probiotics in the treatment and prevention of acute infectious diarrhea in infants and children. They evaluated the effect of L. rhamnosus GG (LGG), L. reuteri, L. acidophilus LB, S. boulardii, Streptococcus thermophilus lactis, L. acidophilus, and L. bulgaricus, and reported that LGG had the most consistent effect. 53 Although the precise mechanism of action for S. boulardii is not fully described, several explanations have been proposed. S. boulardii has antimicrobial activities that could inhibit growth and invasion of pathogens. 54 Geyik et al reported that S. boulardii decreases bacterial gut translocation and improves the intestinal barrier function in the animal model. 55 S. boulardii could neutralize bacterial virulence factors. Pothoulakis et al reported that viable S. boulardii secretes a 54-kDa serine protease able to inhibit binding of Clostridium REVIEW ARTICLE difficile toxin A to specific intestinal receptors of ratileum by degradation of toxin and receptor sites of toxin on the enterocyte cell surface. 56 Recent experiments show that S. boulardii suppresses the host cell adherence that interferes with bacterial colonization. 57 S. boulardii also produces some antiinflammatory factors contributing to regulation of immune responses and antisecretory effects on transepithelial ion transport. Buts et al reported that S. boulardii increases the mucosal immune response and secretory IgA intestinal levels in the animal model. 58 Pooling data of 4 studies performed in children who had rotavirus diarrhea showed a significant reduction in duration of diarrhea (218.07 hours). There are limited data on the mechanism of action of S. boulardii against viral diarrhea (such as Rotavirus, Adenovirus, and Norovirus). 59 Pooling data of 2 studies performed in children who had diarrhea caused by E. histolytica showed that using S. boulardii may also reduce duration of diarrhea. SavasErdeve et al evaluated the efficacy of 250 mg/day S. boulardii in combination with metronidazole and metronidazole alone in treatment of diarrhea caused by amoeba. There was no significant difference in effectiveness between S. boulardii in addition to antibiotic and metronidazole alone. Using a lower probiotic dose may help to explain why the addition of S. boulardii to antibiotic treatment was not effective. Another study evaluated the efficacy of the addition of 500 mg/day S. boulardii to antibiotic for treating childhood diarrhea with the same ethiology. There was a 27.8-hour reduction in duration of diarrhea in the treatment group compared with the control group. This antiamebic effect could be explained by some in vitro studies that showed that S. boulardii can reduce the number of red blood cells adhering to amoebae and decrease the number of amoebae bearing red blood cells. 60 More research in this field is required to evaluate the safety and efficacy of S. boulardii and to address the best dosage for treatment of children who have amebic diarrhea.
Our subgroup analysis according to dose of S. boulardii confirmed there might be a direct relationship between the dosage of probiotic and its therapeutic effect.
Most of the studies included in our review did not state the number of viable S. boulardii that was administered to participants. Viability of the microorganism is very important for effectiveness of probiotics. Further studies that include reliable microbiological tests to confirm the viability of S. boulardii must be conducted to determine the most effective dosing schedule.
Our systematic review and meta-analysis indicate that using S. boulardii as adjunct therapy reduces the duration of diarrhea and also may shorten the length of hospital stay, which may provide a social and economic benefit of S. boulardii treatment in combination with ORS in acute childhood diarrhea. Considering that most acute diarrhea is self-limiting and requires no specific treatment, it is necessary to conduct cost-effectiveness analysis in both developing and developed countries to identify whether S. boulardii
FIGURE 5
Forest plot showing the effect of S. boulardii on mean stool frequency on day 3.
should be used in treating childhood diarrhea.
Although included studies in our review did not mention any serious adverse effects related to administration of S. boulardii, these trials were performed in previously healthy children, and susceptible individuals such as children who had malnutrition or immune deficiency were excluded; therefore, the side effects of S. boulardii in these children are unknown. In addition, some adverse events were mostly reported in case reports which are not included in our review. For example, there was a case report of fungemia in an 11-month-old infant who received S. boulardii to prevent diarrhea associated with chemotherapy. 61 It is necessary to evaluate the safety of S. boulardii in these specific populations.
Our review has some limitations that must be considered while interpreting our results. We used a checklist with 4 features to assess the methodological quality of included trials. The studies included in this review were varied in their methodological quality and some studies did not report sufficient information about sequence generation, allocation concealment, blinding, and incomplete outcome data. The definition of diarrhea, theterminationofdiarrhea,andinclusion and exclusion criteria were varied among included studies. Most included studies defined diarrhea according to the WHO' s definition, whereas others did not state any diarrhea definition. Different exclusion criteria were stated in included studies. In most studies exclusion criteria were underlying conditions, such as severe chronic diseases, cystic fibrosis,
FIGURE 6
Forest plot showing the effect of S. boulardii on RR of diarrhea on day 3.
FIGURE 7
Begg' s funnel plot in MD versus SE for studies that reported the effect of S. boulardii on mean duration of diarrhea.
chronic gastrointestinal diseases, short bowel syndrome, food allergy, or any digestive pathology that might interfere with the results, whereas other studies did not consider these criteria. Some studies had a small sample size (eg, n = 27) and other studies did not provide the duration of treatment. There were limited trials among included studies that were conducted in European countries. Canani et al conducted a single blinded trial and reported that S. boulardii had no significant effect on treatment of diarrhea in Italian children. Other studies performed in Asian and Latino American countries showed a significant effect of S. boulardii in the reduction of duration of diarrhea. Considering the difference in morbidity and cause of acute diarrhea in developed and developing countries, it is important to conduct further trials in developed countries.
CONCLUSIONS
Based on our results, administration of S. boulardii in addition to rehydration therapy appears to be effective in the treatment of diarrhea owing to a variety of causes and was not associated with any adverse effects. This systematic review recommends using S. boulardii as adjunct therapy in acute childhood diarrhea. However, more clinical trials are needed to inform the development of evidence-based treatment guidelines. It is necessary to conduct more trials to define the best dosage of S. boulardii for diarrhea from different causes. Further clinical studies are needed to identify causes of diarrhea for each participant, and specially more studies should be performed in children who have bacterial and parasitic diarrhea.
